LivaNova's PolySync Algorithm Boosts OSA Treatment Response to 84.5% in OSPREY Study
Event summary
- LivaNova's PolySync™ programming algorithm achieved an 84.5% cumulative response rate in moderate to severe OSA patients using proximal hypoglossal nerve stimulation (pHGNS).
- The results were presented at SLEEP 2026 by Alan R. Schwartz, M.D., adjunct professor at the University of Pennsylvania.
- PolySync reprogramming converted non-responders into responders, improving both AHI and ODI outcomes.
- LivaNova plans to submit a PMA supplement application for its next-generation OSA device in the second half of 2026.
The big picture
LivaNova's PolySync algorithm represents a significant advancement in treating obstructive sleep apnea, building on the company's strong clinical foundation established by the OSPREY and THN3 RCTs. The ability to reprogram non-responders highlights the potential for personalized neuromodulation to address a broader patient population. This innovation positions LivaNova at the forefront of neuromodulation technology, with implications for both clinical outcomes and market share in the growing OSA treatment landscape.
What we're watching
- Regulatory Approval
- The pace at which LivaNova secures FDA approval for its next-generation OSA device with MRI compatibility and remote configuration capabilities.
- Market Expansion
- Whether PolySync's ability to convert non-responders can expand the addressable patient population for pHGNS therapy.
- Competitive Positioning
- How LivaNova's advanced programming algorithms differentiate it from competitors in the neuromodulation space.